Eli Lilly (LLY)
NYSE Market Open
Eli Lilly & Co. is a global pharmaceutical company focused on discovering, developing, manufacturing, and commercialising prescription medicines. The company has a long history in diabetes care and has expanded into several high-value therapeutic areas, including obesity, oncology, immunology, neuroscience, and cardiometabolic disease. Lilly sells medicines through healthcare systems, pharmacies, hospitals, and specialist channels in the United States and international markets.
A central part of Lilly’s current profile is its cardiometabolic portfolio. Mounjaro, used for type 2 diabetes, and Zepbound, used for chronic weight management, are based on tirzepatide and have become major growth drivers as demand for GLP-1 and related incretin therapies increases. Lilly also markets established diabetes products such as Trulicity, Jardiance, Humalog, and Humulin, giving it broad exposure across modern and legacy diabetes treatment.
Beyond metabolic disease, Lilly has important positions in cancer and immunology. Verzenio is used in certain breast cancer settings, while Jaypirca targets specific blood cancers. Taltz and Olumiant are part of the company’s immunology franchise, addressing inflammatory and autoimmune conditions. In neuroscience, Lilly is active in areas such as Alzheimer’s disease and migraine, supported by a research pipeline that aims to produce differentiated therapies for complex neurological disorders.
The company’s investment case is closely tied to product innovation, clinical trial execution, regulatory approvals, manufacturing capacity, and pricing dynamics. Lilly competes with other large drugmakers but stands out for the scale of its obesity and diabetes opportunity, its strong research base, and its ability to turn specialised medicines into global commercial franchises.
Last updated
- Market Cap
- 982.77B
- P/E
- 38.88
- P/FCF
- 83.12
- P/S
- 13.6
- Enterprise Value
- 1.02T
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Address
- LILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285
Zealthy Launches Enhanced Weight-Loss Care Platform With Integrated Zepbound Access and Insurance Support
Fund manager names 3 non-AI stocks to own as Intel, AMD sink amid broader tech rout
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
Oryn Therapeutics Advances Next Phase of Orynotide™ Macrocyclic Peptide Platform Development with Expanded Leadership Team and Board Anchored by Accomplished Life Sciences Industry Veterans, Company Builders and Drug Developers
New Long-Term Data Shows Lebrikizumab Sustains Atopic Dermatitis Clearance With Less Frequent Dosing and Advances Findings from Dr. Philip Werschler of Spokane Dermatology Clinic
Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis
TheDoseReport Announces Which GLP-1 is Best? Semaglutide and Tirzepatide
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound
[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026
Novo Nordisk’s Wegovy Pill Turns Pricing Pain Into a Volume Bet
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
Eli Lilly stock rises as Retatrutide data boosts obesity drug lead
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight
S&P 500, Nasdaq futures climb as chip stocks stabilize
Dow Jones Industrial Average hits record as investors rotate out of chips
Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema
From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 982.77B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 1.02T
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 38.88
- P/B
P/B ratio compares a company's share price to its book value per share.
- 31.5
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 13.6
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 28.19
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 14.13
- EPS
- 28.35
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.57%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 83.12
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 47.99
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 11.82B
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 81.02%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 21.68%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 1.39
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.5
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.1
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.14
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 3.18M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 1,102.08
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 19.8B | 19.29B | 17.6B | 15.56B | 12.73B |
| Gross profit | 16.22B | 15.92B | 14.59B | 13.11B | 10.5B |
| Operating income | 8.92B | 8.37B | 7.37B | 6.87B | 3.7B |
| EBITDA | 10.29B | 9.57B | 8.86B | 7.5B | 5.77B |
| Net income | 7.4B | 6.64B | 5.58B | 5.66B | 2.76B |
| Basic EPS | 8.27 | 7.4 | 6.22 | 6.3 | 3.07 |
| Diluted EPS | 8.26 | 7.39 | 6.21 | 6.29 | 3.06 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 116.58B | 112.48B | 114.94B | 100.92B | 89.39B |
| Total liabilities | 85.38B | 85.94B | 91.08B | 82.57B | 73.54B |
| Total equity | 31.2B | 26.54B | 23.85B | 18.35B | 15.85B |
| Cash & equivalents | 5.28B | 7.27B | 9.79B | 3.38B | 3.09B |
| Current assets | 54.84B | 55.63B | 62.07B | 49.85B | 41.26B |
| Current liabilities | 36.63B | 35.23B | 40.14B | 39.02B | 30.07B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 5.33B | 3.22B | 8.84B | 3.09B | 1.67B |
| Investing cash flow | -3.92B | -2.8B | -2.98B | -1.83B | -3.35B |
| Financing cash flow | -3.47B | -2.88B | 531M | -1.24B | 1.38B |
| Change in cash | -1.99B | -2.52B | 6.42B | 282.6M | -175M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Yuffa Ilya | View Filing | |
| edgar index | 25-NSE — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 8-K — ELI LILLY & Co | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| edgar index | SD — ELI LILLY & Co | View Filing | |
| edgar index | 424B2 — ELI LILLY & Co | View Filing | |
| edgar index | 8-K — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 424B2 — ELI LILLY & Co | View Filing | |
| edgar index | FWP — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — LILLY ENDOWMENT INC | View Filing | |
| form 4 | Form 4 — LILLY ENDOWMENT INC | View Filing | |
| edgar index | SCHEDULE 13G — ELI LILLY & Co | View Filing | |
| edgar index | PX14A6G — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | SCHEDULE 13G/A — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| edgar index | SCHEDULE 13G/A — ELI LILLY & Co | View Filing | |
| edgar index | DEF 14A — ELI LILLY & Co | View Filing | |
| edgar index | DEFA14A — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| edgar index | PRE 14A — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Dozier Eric | View Filing | |
| form 4 | Form 4 — Dozier Eric | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free